Author Correction: Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease (Scientific Reports, (2013), 3, 1, (1393), 10.1038/srep01393);Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Noelker, Carmen ^a,b   Morel, Lydie ^a   Lescot, Thomas ^a   Osterloh, Anke ^c   Alvarez Fischer, Daniel ^a,b   Breloer, Minka ^c   Henze, Carmen ^a   Depboylu, Candan ^b   Skrzydelski, Delphine ^a   Michel, Patrick P ^a   Dodel, Richard C ^b   Lu, Lixia ^a   Hirsch, Etienne C ^a   Hunot, Stéphane ^a   Hartmann, Andreas ^a  

^a INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; HOMOVANILLIC ACID; TOLL LIKE RECEPTOR 4;

ANIMAL; ARTICLE; CELL DEATH; CORPUS STRIATUM; GENETICS; METABOLISM; MICROGLIA; MOUSE; MOUSE MUTANT; PARKINSONISM;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CELL DEATH; CORPUS STRIATUM; DOPAMINE; HOMOVANILLIC ACID; MICE; MICE, KNOCKOUT; MICROGLIA; PARKINSONIAN DISORDERS; TOLL-LIKE RECEPTOR 4;

EID: 84875123349     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-022-26917-1     Document Type: Erratum

References (24)

1. Fahn, S., Parkinsonism, P. S. & Rowland, L. P. ed. Meritt's neurology 10th ed. New York: Lippincott, 2000, 679-693 (2000).
2. Hirsch, E. C. & Hunot, S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8, 382-397 (2009).
3. McGeer, P. L., Itagaki, S., Boyes, B. E. & McGeer, E. G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291 (1988).
4. Moresco, E. M., LaVine, D. & Beutler, B. Toll-like receptors. Curr Biol 21, R488-493 (2011).
5. Laflamme, N. & Rivest, S. Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components. Faseb J 15, 155-163 (2001). (Pubitemid 32061666)
6. Ros-Bernal, F. et al. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc Natl Acad Sci USA 108, 6632-6637 (2011).
7. Stefanova, N. et al. Toll-like receptor 4 promotes alpha-synuclein clearance and survival of nigral dopaminergic neurons. Am J Pathol 179, 954-963 (2011).
8. Beraud, D. & Maguire-Zeiss, K. A. Misfolded alpha-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease. Parkinsonism Relat Disord 18 Suppl 1, S17-20 (2012).
9. Beraud, D. et al. alpha-Synuclein Alters Toll-Like Receptor Expression. Front Neurosci 5, 80 (2011).
10. Cote, M., Drouin-Ouellet, J., Cicchetti, F. & Soulet, D. The critical role of the MyD88-dependent pathway in non-CNS MPTP-mediated toxicity. Brain Behav Immun 25, 1143-1152 (2011).
11. Drouin-Ouellet, J. et al. The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration. J Neuroinflammation 8, 137 (2011).
12. Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085-2088 (1998). (Pubitemid 29001265)
13. Hamre, K., Tharp, R., Poon, K., Xiong, X. & Smeyne, R. J. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res 828, 91-103 (1999). (Pubitemid 29236478)
14. Brochard, V. et al. Infiltration of CD41lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119, 182-192 (2009).
15. Alvarez-Fischer, D. et al. Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid. JNeurochem 107, 701-711 (2008).
16. Skrzydelski, D. et al. The chemokine stromal cell-derived factor-1/CXCL12 activates the nigrostriatal dopamine system. J Neurochem 102, 1175-1183 (2007). (Pubitemid 47174242)
17. Hirsch, E., Graybiel, A. M. & Agid, Y. A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345-348 (1988).
18. Depboylu, C. et al. Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease. J Neuroimmunol 236, 39-46 (2011).
19. Franklin, K. B. J. a. P. George The mouse brain in stereotaxic coordinates. Book (ISBN 0122660706 ) (1997).
20. Panaro, M. A. et al. Expression of TLR4 and CD14 in the Central Nervous System (CNS) in a MPTP Mouse Model of Parkinson's-Like Disease. Immunopharmacol Immunotoxicol 1-12 (2008).
21. Lin, J. J., Chen, C. H., Yueh, K. C., Chang, C. Y. & Lin, S. Z. A CD14 monocyte receptor polymorphism and genetic susceptibility to Parkinson's disease for females. Parkinsonism Relat Disord 12, 9-13 (2006). (Pubitemid 43037147)
22. Hopkins, W. J. et al.Quantitative trait loci associated with susceptibility to bladder and kidney infections induced by Escherichia coli in female C3H/HeJmice. J Infect Dis 199, 355-361 (2009).
23. Kanzler, H., Barrat, F. J., Hessel, E. M. & Coffman, R. L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13, 552-559 (2007). (Pubitemid 46830615)
24. Hennessy, E. J., Parker, A. E. & O'Neill, L. A. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 9, 293-307 (2010).